Updated: Bristol Myers shakes up R&D leadership ahead of patent cliff

Bristol Myers Squibb is overhauling its research and development organization, with the company's research chief departing as part of what coverage describes as an evolution of the company's structure. According to reporting from BioSpace and BioPharma Dive, the R&D head is leaving amid a broader restructure. Fierce Biotech reports that BMS is reuniting its R&D divisions under Cristian Massacesi, while Robert Plenge departs. Reuters coverage states that Bristol Myers is merging its scientific and clinical teams under a new R&D structure. Endpoints News frames the leadership shake-up as occurring ahead of a patent cliff. The coverage emphasizes that the reorganization consolidates previously separate R&D functions into a unified leadership model. The timing matters because Bristol Myers faces looming patent expirations on key products, a period commonly referred to as a patent cliff, during which exclusive market protection ends and generic competition can erode revenue. By merging scientific and clinical teams under one executive, the company appears to be seeking faster decision-making and more integrated drug development as it prepares for that revenue pressure. Coverage does not yet specify the financial terms of the departure, the effective date of Massacesi's appointment, or which specific products are driving the patent cliff timeline. What to watch next depends on facts not yet in the coverage: whether additional leadership changes follow, how the merged R&D organization affects the pipeline, and what pipeline readouts or regulatory milestones Bristol Myers discloses as the patent expiration window approaches.